Efficacy of anakinra treatment in pediatric rheumatic diseases: Our single-center experience

OBJECTIVES: This study aims to present our experience on anakinra, a recombinant interleukin-1 (IL-1) receptor antagonist, and efficacy results in pediatric rheumatic diseases in our clinic. PATIENTS AND METHODS: Between July 1(st), 2016 and July 1(st), 2020, a total of 33 pediatric patients (18 mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Demir, Ferhat, Gürler, Eda, Sözeri, Betül
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791547/
https://www.ncbi.nlm.nih.gov/pubmed/36589607
http://dx.doi.org/10.46497/ArchRheumatol.2022.8998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791547/
https://www.ncbi.nlm.nih.gov/pubmed/36589607
http://dx.doi.org/10.46497/ArchRheumatol.2022.8998

Ejemplares similares